Denmark Lisbeth Nielsen of the Danish Health Data Authority outlines the organisation’s purpose and mission, how it contributed to Denmark’s robust COVID-19 response, and the challenges of making Denmark’s comprehensive patient data sets available to researchers while maintaining patient confidentiality and trust. One of the Health Data Authority’s most important…
Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…
Singapore Alan Goh of NDR Medical Technology, a pioneer in intelligent navigation and image processing for minimally invasive surgery, introduces the progress of the company to date, how its technology has been received by surgeons, and the growth strategy he has put in place. We are trying to overcome the…
Global Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making. Artificial intelligence (AI) has been creating a buzz in…
Switzerland Andrea Emilio Rizzoli of the Dalle Molle Institute for Artificial Intelligence, among the top 10 in the world in its field of research, outlines the focus of the Institute today, the synergies between AI and healthcare, and how pharma companies might structure their AI investments in the future. When…
Singapore Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem. We…
Europe With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head of Digital Transformation Saskia Steinacker argues that the time is now for pharma executives to start preparing themselves and their teams for the future. “We are in Healthcare. We are…
Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries. As a true believer in the power of technology to transform health,…
Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’. Data is the new oil, but biomedical data – despite its abundance…
Japan Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as the wider implications for greater use of artificial intelligence in the biotechnology field. The greatest strength of Molcure’s system…
Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19. Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…
See our Cookie Privacy Policy Here